Cargando…

Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer

BACKGROUND: Novel approaches are needed for breast cancer patients in whom standard therapy is not effective. 2-Deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) was evaluated as a potential radiomolecular therapy agent in breast cancer animal models and, retrospectively, in patients with metastatic breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Moadel, Renee M, Nguyen, Andrew V, Lin, Elaine Y, Lu, Ping, Mani, Joseph, Blaufox, M Donald, Pollard, Jeffrey W, Dadachova, Ekaterina
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314404/
https://www.ncbi.nlm.nih.gov/pubmed/14580255
_version_ 1782121112206835712
author Moadel, Renee M
Nguyen, Andrew V
Lin, Elaine Y
Lu, Ping
Mani, Joseph
Blaufox, M Donald
Pollard, Jeffrey W
Dadachova, Ekaterina
author_facet Moadel, Renee M
Nguyen, Andrew V
Lin, Elaine Y
Lu, Ping
Mani, Joseph
Blaufox, M Donald
Pollard, Jeffrey W
Dadachova, Ekaterina
author_sort Moadel, Renee M
collection PubMed
description BACKGROUND: Novel approaches are needed for breast cancer patients in whom standard therapy is not effective. 2-Deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) was evaluated as a potential radiomolecular therapy agent in breast cancer animal models and, retrospectively, in patients with metastatic breast cancer. METHODS: Polyoma middle T antigen (PyMT) and mouse mammary tumor virus-NeuT transgenic mice with tumors 0.5–1 cm in diameter were imaged with (18)F-FDG, and tumor to liver ratios (TLRs) were calculated. The radiotoxicity of (18)F-FDG administration was determined in healthy mice. PyMT mice with small (0.15–0.17 cm) and large (more than 1 cm) tumors were treated with 2–4 mCi of (18)F-FDG, and control C3H/B6 mice with 3 mCi of (18)F-FDG. At 10 days after treatment the tumors and control mammary glands were analyzed for the presence of apoptotic and necrotic cells. Five patients with breast cancer and metastatic disease were evaluated and standardized uptake values (SUVs) in tumors, maximum tolerated dose, and the doses to the tumor were calculated. RESULTS: Doses up to 5 mCi proved to be non-radiotoxic to normal organs. The (18)F-FDG uptake in mouse tumors showed an average TLR of 1.6. The treatment of mice resulted in apoptotic cell death in the small tumors. Cell death through the necrotic pathway was seen in large tumors, and was accompanied by tumor fragmentation and infiltration with leukocytes. Normal mammary tissues were not damaged. A human (18)F-FDG dose delivering 200 rad to the red marrow (less than 5% damage) was calculated to be 4.76 Ci for a 70 kg woman, and the dose to the tumors was calculated to be 220, 1100 and 2200 rad for SUVs of 1, 5 and 10, respectively. CONCLUSION: We have shown that positrons delivered by (18)F-FDG to mammary tumors have a tumoricidal effect on cancer cells. The study of breast cancer patients suggests that the tumor and normal organ dosimetry of (18)F-FDG makes it suitable for therapy of this malignancy.
format Text
id pubmed-314404
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-3144042004-01-17 Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer Moadel, Renee M Nguyen, Andrew V Lin, Elaine Y Lu, Ping Mani, Joseph Blaufox, M Donald Pollard, Jeffrey W Dadachova, Ekaterina Breast Cancer Res Research Article BACKGROUND: Novel approaches are needed for breast cancer patients in whom standard therapy is not effective. 2-Deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) was evaluated as a potential radiomolecular therapy agent in breast cancer animal models and, retrospectively, in patients with metastatic breast cancer. METHODS: Polyoma middle T antigen (PyMT) and mouse mammary tumor virus-NeuT transgenic mice with tumors 0.5–1 cm in diameter were imaged with (18)F-FDG, and tumor to liver ratios (TLRs) were calculated. The radiotoxicity of (18)F-FDG administration was determined in healthy mice. PyMT mice with small (0.15–0.17 cm) and large (more than 1 cm) tumors were treated with 2–4 mCi of (18)F-FDG, and control C3H/B6 mice with 3 mCi of (18)F-FDG. At 10 days after treatment the tumors and control mammary glands were analyzed for the presence of apoptotic and necrotic cells. Five patients with breast cancer and metastatic disease were evaluated and standardized uptake values (SUVs) in tumors, maximum tolerated dose, and the doses to the tumor were calculated. RESULTS: Doses up to 5 mCi proved to be non-radiotoxic to normal organs. The (18)F-FDG uptake in mouse tumors showed an average TLR of 1.6. The treatment of mice resulted in apoptotic cell death in the small tumors. Cell death through the necrotic pathway was seen in large tumors, and was accompanied by tumor fragmentation and infiltration with leukocytes. Normal mammary tissues were not damaged. A human (18)F-FDG dose delivering 200 rad to the red marrow (less than 5% damage) was calculated to be 4.76 Ci for a 70 kg woman, and the dose to the tumors was calculated to be 220, 1100 and 2200 rad for SUVs of 1, 5 and 10, respectively. CONCLUSION: We have shown that positrons delivered by (18)F-FDG to mammary tumors have a tumoricidal effect on cancer cells. The study of breast cancer patients suggests that the tumor and normal organ dosimetry of (18)F-FDG makes it suitable for therapy of this malignancy. BioMed Central 2003 2003-08-22 /pmc/articles/PMC314404/ /pubmed/14580255 Text en Copyright © 2003 Moadel et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Moadel, Renee M
Nguyen, Andrew V
Lin, Elaine Y
Lu, Ping
Mani, Joseph
Blaufox, M Donald
Pollard, Jeffrey W
Dadachova, Ekaterina
Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title_full Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title_fullStr Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title_full_unstemmed Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title_short Positron emission tomography agent 2-deoxy-2-[(18)F]fluoro-D-glucose has a therapeutic potential in breast cancer
title_sort positron emission tomography agent 2-deoxy-2-[(18)f]fluoro-d-glucose has a therapeutic potential in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC314404/
https://www.ncbi.nlm.nih.gov/pubmed/14580255
work_keys_str_mv AT moadelreneem positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT nguyenandrewv positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT linelainey positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT luping positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT manijoseph positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT blaufoxmdonald positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT pollardjeffreyw positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer
AT dadachovaekaterina positronemissiontomographyagent2deoxy218ffluorodglucosehasatherapeuticpotentialinbreastcancer